Loading organizations...
North Haven Capital, largely recognized through its "North Haven Capital Partners" funds, functions as the private equity and alternative investments division of Morgan Stanley Investment Management. It structures and manages various investment funds, strategically deploying capital across private markets, encompassing buyout, growth equity, and venture capital to generate long-term value.
The "North Haven" brand originated within Morgan Stanley Investment Management as its dedicated platform for private market endeavors. While specific individual founders are not typically highlighted, its establishment underscores Morgan Stanley's commitment to sophisticated alternative investment solutions and evolving capabilities.
These investment vehicles primarily serve institutional investors and high-net-worth individuals seeking private asset exposure. North Haven Capital aims for attractive risk-adjusted returns and capital appreciation by identifying and supporting promising companies. Its long-term vision is to expand investment strategies and reinforce its global leadership in private markets capital allocation.
North Haven Capital has 2 tracked investments across 1 company. The latest tracked deal is $4.0M Other Equity in Cecelia Health in September 2018.
| Date | Company | Round | Lead Investor(s) | Co-Investor(s) |
|---|---|---|---|---|
| Sep 4, 2018 | Cecelia Health | $4.0M Other Equity | SJF Ventures | Blue Cross And Blue Shield OF Nebraska, C&B Capital, StartUp Health |
| Sep 1, 2018 | Cecelia Health | $4.0M Series U | SJF Ventures | OurCrowd, Rose Tech Ventures, Chaim Meir Tessler, Blue Cross And Blue Shield OF Nebraska, C&B Capital, StartUp Health |